FUL.L Regulatory News (FUL)

1 Mar 2005 07:03

Fulcrum Pharma PLC01 March 2005 For immediate release 1 March 2005 Fulcrum Pharma plc ("Fulcrum" or "the Company") Fulcrum to Present at Senior Executive Networking Evening "What investors in Pharma and Biotech are looking for and how to meet those expectations" Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcingservices company, announces today that its CEO, Dr Jon Court, will be presentingat a Senior Executive Networking Evening: "What Investors in Pharma and Biotechare Looking for and How to Meet Those Expectations" on Tuesday 1 March 2005 atthe Four Seasons Hotel, London. Dr Court will take part in a panel discussiontogether with a representative from Astra Zeneca and Advent Partners. MichaelForer, Managing Director of BioScience Managers Ltd, will chair the event. The essence of Dr Court's presentation at the above event will be on 'the proofof value'. He will discuss what management in pharma and biotech need to do todemonstrate their projects, portfolio are winners and how to have a balancedapproach to creating value. A copy of the presentation will be available on theFulcrum web site (www.fulcrumpharma.com) For further information, please contact:Fulcrum Pharma PLC Tel: 0870 710 7152Jon Court, CEO Buchanan Communications Tel: 020 7466 5000Mary-Jane Johnson Notes to Editors: About Fulcrum Pharma Fulcrum Pharma plc is an independent, drug development company that is the firstto offer global virtual drug development and strategic outsourcing services tothe pharmaceutical industry. The Company has expertise in the design, executionand delivery of drug development programmes and relies on state of the artinformation technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe that there isthe capacity to deliver products faster and more efficiently to the globalpharmaceutical market. Fulcrum does this by using its skills in the design ofdrug programmes that deliver the necessary information for decision-making andproduct registration. In so doing, Fulcrum works closely with its clients tomeet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the LondonStock Exchange having successfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange